H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome by Ruscitti, P. et al.
H-ferritin and proinflammatory cytokines are increased in the bone
marrow of patients affected by macrophage activation syndrome
P. Ruscitti ,* P. Cipriani,*
P. Di Benedetto,* V. Liakouli,*
O. Berardicurti,* F. Carubbi,*
F. Ciccia,† G. Guggino ,†
G. Triolo† and R. Giacomelli*
*Division of Rheumatology, Department of
Biotechnological and Applied Clinical Sciences,
University of L’Aquila, L’Aquila, Italy, and
†Division of Rheumatology, Department of
Internal Medicine, University of Palermo,
Palermo, Italy
Accepted for publication 21 September 2017
Correspondence: P. Ruscitti, Department of
Biotechnological and Applied Clinical Science,
Rheumatology Unit, School of Medicine,
University of L’Aquila, Delta 6 Building, Via
dell’Ospedale, 67100 L’Aquila, Italy.
E-mail: pieroruscitti@live.com
Summary
Macrophage activation syndrome (MAS) is hyperinflammatory life-
threatening syndrome, associated typically with high levels of serum ferritin.
This is an iron storage protein including heavy (H) and light (L) subunits,
categorized on their molecular weight. The H-/L subunits ratio may be
different in tissues, depending on the specific tissue and pathophysiological
status. In this study, we analysed the bone marrow (BM) biopsies of adult
MAS patients to assess the presence of: (i) H-ferritin and L-ferritin; (ii)
CD681/H-ferritin1 and CD681/L-ferritin1; and (iii) interleukin (IL)-1b,
tumour necrosis factor (TNF) and interferon (IFN)-g. We also explored
possible correlations of these results with clinical data. H-ferritin, IL-1b,
TNF and IFN-g were increased significantly in MAS. Furthermore, an
increased number of CD681/H-ferritin1 cells and an infiltrate of cells
co-expressing H-ferritin and IL-12, suggesting an infiltrate of M1
macrophages, were observed. H-ferritin levels and CD681/H-ferritin1 cells
were correlated with haematological involvement of the disease, serum
ferritin and C-reactive protein. L-ferritin and CD681/L-ferritin1 cells did
not correlate with these parameters. In conclusion, during MAS, H-ferritin,
CD681/H-ferritin1 cells and proinflammatory cytokines were increased
significantly in the BM inflammatory infiltrate, pointing out a possible
vicious pathogenic loop. To date, H-ferritin and CD681/H-ferritin1 were
associated significantly with haematological involvement of the disease,
suggesting biomarkers assessing severity of clinical picture.
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Introduction
Macrophage activation syndrome (MAS) is a hyperinflam-
matory syndrome, associated usually with systemic juvenile
idiopathic arthritis and adult-onset Still’s disease (AOSD)
[1–4]. Due to this close association, it has been suggested
that MAS and AOSD may represent one part of the same
disease spectrum, of which AOSD may be considered the
milder form [5]. In this context, it has been shown that
MAS occurrence may be misdiagnosed due to immunosup-
pressive drugs used to treat AOSD flare, thus reducing the
reported prevalence of this syndrome [6,7]. Furthermore,
patients affected by systemic lupus erythematosus (SLE)
may also experience MAS [8]. Continuous high fever, hep-
atosplenomegaly, severe peripheral blood cytopenia and
haemophagocytosis by activated macrophages in bone
marrow (BM) are typical features of these patients [1–8].
In contrast to paediatric patients, the therapeutic strategies
of adults derive mainly from case–series and retrospective
experiences [9–11]. In this context, the clearance of possi-
ble triggers, immunosuppressive therapeutic strategies and
supportive care are considered the main therapeutic strat-
egies [10]. Despite aggressive therapeutic strategies, MAS is
one of the most critical clinical disorders in adults, evolving
to multiple organ failure and unfavourable outcome [1,8].
This result may be possibly related, in adult age, with an
increased presence of co-morbidities, the latter known to
be predictive of a more severe outcome in MAS patients as
observed in other rheumatic diseases [3,8,12].
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Recently, a multi-layer MAS pathogenic model during
inflammatory rheumatic diseases has been proposed [2].
Genetic factors, proinflammatory milieu associated with the
underlying rheumatic disease, trigger factors and the uncon-
trolled activation of macrophages and T cells may lead to the
development of cytokine storm and MAS [13,14]. Activation
of cytotoxic CD8 T lymphocytes with production of
macrophage-activating cytokines, such as interferon (IFN)-g,
is an early event in MAS pathogenesis. Defects in
granulocyte-mediated cytotoxicity, enhanced antigen presen-
tation and repeated stimulation of Toll-like receptors deter-
mine extensive production/release of tumour necrosis factor
(TNF) and interleukin (IL)-1b [13,14]. The consequent
activation and expansion of monocytes and macrophages
lead to pathological haematophagocytosis [1,2,13,14]. In this
context, it has been considered that macrophages are catego-
rized in M1 (classically activated), releasing proinflammatory
mediators, and M2 (alternatively activated), modulating the
inflammatory response [15].
During MAS, a possible pathogenic role of ferritin has
been suggested and has been included in the so-called
‘hyperferritinaemic syndrome’ [16,17]. Ferritin is an intra-
cellular iron storage protein including 24 subunits. These
are categorized, according to molecular weight, as heavy
(H) subunits and light (L) subunits. Ferritin enriched in L
subunits (L-ferritin) has been found in liver and in spleen,
whereas ferritin enriched in H subunits (H-ferritin) may be
observed mainly in heart and kidneys [17]. Possible causes
of hyperferritinaemia in these patients include increased
production to sequestrate free iron of released haemoglo-
bin due to erythrophagocytosis, reduced tissue clearance
and enhanced production by macrophages [16,17].
In this study, we aimed to investigate H-and L-ferritin in
inflammatory BM infiltrate of MAS patients during full-
blown syndrome. Macrophage subsets expressing H-and
L-ferritin were also assessed. Furthermore, we evaluated
IL-1b, TNF, IFN-g and their possible co-localization with
ferritin within inflammatory cells. Finally, any possible
clinical correlation of these data with the severity of the dis-
ease was analysed.
Patients and methods
A retrospective evaluation of BM biopsies obtained from
adult MAS patients admitted to the Rheumatology Clinic
of L’Aquila University and Rheumatology Clinic of Palermo
University during the last 10 years was performed. MAS
patients were diagnosed according to 2004 haemophago-
cytic lymphohistiocytosis (HLH) diagnostic guidelines cri-
teria [18]. In this study, we also evaluated 10 biopsies
derived from BM-donors, used as healthy controls (HCs).
For each patient we analysed age, gender, values of white
blood cell count (WBC), red blood cells (RBC), haemoglo-
bin (HB), platelet count (PLT), serum ferritin, erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP),
aspartate aminotransferase (ASAT) and alanine amino-
transferase (ALAT) during the full-blown syndrome.
The local ethics committee approved the study (ASL1
Avezzano-Sulmona-L’Aquila, L’Aquila, Italy, protocol num-
ber 0122353/17) that was performed according to Good
Clinical Practice guidelines and Declaration of Helsinki.
Histological analysis of biopsies
Samples were stained with anti-H-ferritin, anti-L-ferritin,
anti-CD68, anti-CD163, anti-IL-1b, anti-IL-12, anti-IFN-g
and anti-TNF antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), as reported previously [16]. Samples were
acquired using a light microscope (Olympus BX53) and
immunofluorescence images by CellSens software (Olympus
America Inc., Center Valley, PA, USA). Cells double-positive
for both CD68/H-ferritin and CD68/L-ferritin were counted
in sections from randomly selected areas of the BM, count-
ing at least 500 nucleated cells (320 magnification) by using
NIHimageJ version 1.43 (http://rsbweb.nih.gov/ij/) freeware.
Statistical analysis
To compare the results of MAS patients and HCs, the
Mann–Whitney U-test was considered appropriate due to
the non-parametric distribution of our data. To assess cor-
relations among tissue H- and L-ferritin, the numbers of
double-positive cells for CD68 and H-ferritin (CD681/H-
ferritin1 or double-positive cells for CD68 and L-ferritin
(CD681/L-ferritin1) and clinical features, Spearman’s cor-
relation analysis and linear regression were used. The same
analysis was performed to evaluate a possible correlation
among H-ferritin and IL-1b, TNF and IFN-g. A P-val-
ue< 005 expressed a statistically significant result. We
used GraphPad Prism version 5.0 for all statistical analyses.
Results
Demographic and clinical features
In this study, we evaluated BM biopsies of 10 patients affected
by MAS collected during the full-blown syndrome. All these
adult patients were affected by proinflammatory rheumatic
disease (eight patients by AOSD, two patients by SLE), and
MAS occurred during disease flare or severe infection. We
observed that two patients experienced MAS after severe
Epstein–Barr virus (EBV) infection and two patients
during Gram-negative sepsis, due to immunosuppressive
treatments administered for underlying rheumatic disease.
All these patients showed peripheral blood cytopenia [WBC,
mean6 standard deviation (s.d.) 3236 144, 103/ml;
RBC5 3226 070, 103/ml; PLT5 45526 2660, 103/ml],
increased serum levels of ferritin (2842706 56970 ng/ml),
marked increase of inflammatory markers (ESR5 63876
3019, mm/h; CRP5 51596 4692, mg/day). The clinical
data are shown in Table 1.
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H-ferritin is increased in BM and correlates with
clinical features
We observed a granular morphological pattern of
H-ferritin and L-ferritin immunoreactivity, including cyto-
plasmatic and extracellular localization, using immunoflu-
orescence. As shown in Fig. 1, H-ferritin was increased in
BM samples of MAS patients when compared with both
L-ferritin and HCs (P< 00001 for each comparison),
analysing the optical density of immunofluorescence.
Conversely, L-ferritin was not increased when compared to
HCs. Subsequently, clinical correlations among these histo-
logical data and severity of the clinical picture were eval-
uated. Our analyses showed that the peripheral blood
cytopenia of these patients were correlated inversely with
the levels of H-ferritin in the BM of MAS. Increased values
of H-ferritin levels correlated with decreased WBC and PLT
counts (P5 001, P5 00001; respectively). A further cor-
relation was observed among tissue H-ferritin and the
inflammatory markers. H-ferritin was correlated statisti-
cally with both serum ferritin and CRP levels (P5 0012;
P5 00058, respectively), as shown in Fig. 2. No correlation
was observed among RBC count, levels of HB, ESR, ASAT,
ALAT and H-ferritin. The correlations among L-ferritin
and clinical data did not show significant results.
IL-1b, TNF, IFN-g and H-ferritin
Proinflammatory cytokines were increased significantly in
BM samples of MAS patients when compared with HCs
analysing the immunofluorescence of our samples. Specifi-
cally, a marked increase of IL-1b was observed in BM of
MAS patients (P5 00002). In addition, the analyses
showed a significant correlation between the tissue expres-
sion of H-ferritin and IL-1b (P5 0006). Interestingly,
H-ferritin and IL-1b co-localized in the BM samples of our
patients, as shown in Fig. 3.
Fig. 1. Expression of H-ferritin in bone marrow samples of macrophage activation syndrome (MAS) patients. (a) high H-ferritin (red) and low
tissue expression of L-ferritin (green) may be observed, respectively; (b) low H-ferritin expression may be reported in healthy controls (HCs);
(c) H-ferritin was increased significantly when compared with L-ferritin increased and HCs, analysing immunostaining optical density
(***P< 00001).
Table 1. Demographic and clinical features of evaluated macrophage
activation syndrome (MAS) patients
Clinical data Patients
Women (men) 4 (6)
Age (years6 s.d.) 58206 1310
Underlying disease, number (%) 10 (100%)
AOSD 8 (80%)
SLE 2 (20%)
Trigger factor, number (%)
Flare of the disease 6 (60%)
Severe infection 4 (40%)
Comorbidities, number (%) 4 (40%)
Time of follow-up, months mean6 s.d. 6966 282
MAS-related death, number (%) 5 (50%)
Laboratory parameters
WBC (103/ml), mean6 s.d. 3236 144
RBC (103/ml), mean6 s.d. 3226 070
HB (g/dl), mean6 s.d. 8796 155
PLT (103/ml), mean6 s.d. 45526 2660
Serum ferritin (ng/ml), mean6 s.d. 2842706 56970
ESR (mm/h), mean6 s.d. 63876 3019
CRP (mg/l), mean6 s.d. 51596 4692
Triglycerides (mg/dl), mean6 s.d. 220026 7125
ASAT (IU/l), mean6 s.d. 84236 5197
ALAT (IU/l), mean6 s.d. 145286 9423
Therapies
High-dosage steroids pulses, number (%) 10 (100%)
Methylprednisolone pulses 1000 mg/die 7 (70%)
Methylprednisolone pulses 500 mg/die 3 (30%)
Immunosuppressive drugs, number (%) 5 (50%)
Cyclosporin A 5 (50%)
ALAT5alanine aminotransferase; AOSD5 adult-onset Still’s dis-
ease; ASAT5aspartate aminotransferase; CRP5C-reactive protein;
ESR5 serum ferritin, erythrocyte sedimentation rate; HB5 haemo-
globin; MAS5macrophage activation syndrome; PLT5platelet
count; RBC5 red blood cells; SLE5 systemic lupus erythematosus;
WBC5white blood cell count.
H-ferritin in MAS
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Furthermore, we showed a significant increase of TNF in
the BM of evaluated patients when compared with HCs
(P5 0002) (Fig. 4). Similarly, a marked increase of IFN-g
was observed when compared with HCs (P< 00001).
However, we did not report correlation or co-localization
among these proinflammatory cytokines and H-ferritin.
CD681/H-ferritin1 macrophages are increased and
correlate with clinical features
In our MAS patients, we reported that H-ferritin co-local-
ized with CD68, as shown in Fig. 5. Furthermore, macro-
phages expressing H-ferritin in the inflammatory infiltrate
were increased significantly when compared with HCs
Fig. 2. Correlation of H-ferritin with clinical
features. (a,b) Increased values of H-ferritin
were correlated with decreased white blood
cells (WBC) and platelet (PLT) counts,
respectively; (c) significantly and (d) increased
values of H-ferritin tissue were correlated
significantly with increased values of serum
ferritin and C-reactive protein (CRP),
respectively.
Fig. 3. Expression interleukin (IL)-1b in bone
marrow of macrophage activation syndrome
(MAS) patients and its correlation with H-
ferritin. (a) Increased IL-1b (green) levels and
co-localization (arrows) between H-ferritin
(red), and this cytokine may be observed in
the inflammatory bone marrow infiltrate;
(b) reduced IL-1b expression in healthy
controls (HCs); (c) in MAS patients, IL-1b
was increased significantly when compared
with HCs (***P< 0001); (d) IL-1b was
correlated significantly with H-ferritin.
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(P5 0006) (Fig. 5). In the same samples, although we
observed a weak co-localization between CD68 and
L-ferritin, these cells did not differ significantly when com-
pared with HCs. We analysed and compared the number
of CD681/H-ferritin1 cells with the number of CD68-/H-
ferritin1 cells, pointing out that a large percentage of
H-ferritin1 cells expressed CD68 (CD681/H-ferritin1 cells:
5 median, range5 27; 90 versus CD68-/H-ferritin1 cells
17 median, range5 15; 22; P< 00001). In addition, we
analysed possible co-localizations among the H-ferritin and
IL-12, which is considered an M1 macrophage marker, and
CD163, which is considered an M2 macrophage marker, as
shown previously [19,20]. As shown in Fig. 5, a co-
localization between H-ferritin and IL-12 was observed.
Conversely, a weaker co-expression between H-ferritin and
CD163 was shown. We analysed and compared the number
of IL-121/H-ferritin1 cells with the number of CD163/H-
ferritin1 cells, indicating that a large percentage of
H-ferritin1 cells expressed IL-12 (IL-121/H-ferritin1 cells:
32 median, range5 16; 61) versus CD1631/H-ferritin1
cells 16 median, range5 13; 27; P5 00002) and suggest-
ing an increased percentage of M1 macrophages in BM
inflammatory infiltrate during MAS full-blown syndrome.
In addition, clinical correlations among CD681/
ferritin1 cells and severity of the clinical picture were
assessed. Our analyses showed that the peripheral blood
cytopenia of these patients were correlated inversely with
the number of BM CD681/H-ferritin1 cells in the inflam-
matory BM infiltrate. Increased values of CD681/H-
ferritin1 cells in the BM inflammatory infiltrate of our
patients correlated with reduced WBC and the PLT counts
(P5 003, P5 00007, respectively). Furthermore, CD681/
H-ferritin1 cells were correlated significantly with both
serum ferritin and CRP levels (P5 00088; P5 0049;
respectively). Figure 6 shows these statistical analyses. ESR,
RBC count and HB levels did not correlate with CD681/H-
ferritin1 cells. pCD681/L-ferritin1 cells in the BM inflam-
matory infiltrate of MAS patients did not correlate with
these clinical parameters.
Discussion
In our study, H-ferritin, CD681/H-ferritin1 cells and
proinflammatory cytokines, IL-1b, TNF, IFN-g, were
increased markedly in BM inflammatory infiltrate of MAS
patients. Of note, H-ferritin and CD681/H-ferritin1 cells
Fig. 4. Increased expression of tumour necrosis factor (TNF) and interferon (IFN)-g in bone marrow of macrophage activation syndrome (MAS)
patients. (a) Increased IFN-g (green) levels and H-ferritin (red) may be described in MAS; (b) reduced IFN-g levels in healthy controls (HCs);
(c) IFN-g was increased significantly when MAS patients were compared with HCs (***P< 0001); (d) increased TNF (green) levels and
H-ferritin (red) may be observed in MAS; (e) reduced TNF levels in HCs; (f) TNF was increased significantly when MAS patients were
compared with HCs (***P< 0001).
H-ferritin in MAS
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Fig. 5. CD68 macrophages expressing H-ferritin in bone marrow infiltrate of macrophage activation syndrome (MAS) patients. (a) CD681/
H-ferritin1 cells (arrows) may be described in the bone marrow (BM) of MAS patients; (b) reduced CD681/H-ferritin1 cells in BM of healthy
controls (HCs); (c) CD681/H-ferritin1 cells was increased significantly in MAS when compared with HCs (***P< 0001); (d) co-localization of
H-ferritin (red) and interleukin (IL)-12 (green) may be observed, suggesting M1 macrophages; (e) CD1631 cells (green) showed weaker co-
localization with H-ferritin (red).
Fig. 6. Correlation between CD681/
H-ferritin1 cells, haematological involvement
and inflammatory markers. (a,b) Increased
CD681/H-ferritin1 was correlated with
decreased white blood cell (WBC) and
decreased platelet (PLT) counts, respectively;
(c,d) CD681/H-ferritin1 was correlated
significantly with serum ferritin and
C-reactive protein (CRP).
P. Ruscitti et al.
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were correlated significantly with the haematological
involvement of our patients, suggesting possible bio-
markers of severity.
During MAS, the massive release/production of proin-
flammatory cytokines may induce H-ferritin expression by
activation of specific transcription factors, such as ferritin 2
(FER2), which may in turn activate production of further
proinflammatory cytokines, triggering a possible vicious
loop [21–26]. In fact, we observed high H-ferritin in the BM
of MAS patients and co-localization as well as a correlation
between H-ferritin and IL-1b, a possibly therapeutic target
in MAS and rheumatic diseases [27–31]. Furthermore, a spe-
cific receptor for H-ferritin on immune cells has also been
reported [32]. The specific binding between H-ferritin and
the T cell immunoglobulin and mucin domain-containing
protein-2 (TIM-2) receptor may modulate the inflammatory
process. This is a member of the TIM gene family and is
expressed by T helper type 2 (Th2) cells and macrophages in
the context of the proinflammatory milieu [32,33]. The
binding H-ferritin/TIM-2 may activate these immune cells,
leading to subsequent pathogenic proinflammatory process
[12,18–21]. Taking together all these mechanisms, it is possi-
ble to speculate that the enhanced tissue expression of
H-ferritin, via a vicious loop, may perpetuate the production
of proinflammatory cytokines, possible therapeutic targets
in MAS [16,17,22,23,27,28].
In our samples, we described macrophages co-expressing
CD68 and H-ferritin that were increased in the BM infil-
trate of MAS. These data may confirm that, after proin-
flammatory stimuli, macrophages may release H-ferritin,
confirming their role in ferritin production [34]. Interest-
ingly, H-ferritin co-localized with IL-12, a marker of M1-
macrophages, associated with increased production of
proinflammatory molecules. Macrophages are polarized by
environment, mainly the cytokine milieu, towards distinct
functional programmes, categorized as M1 and M2 path-
ways. Massive production of IL-1b, INF-g and TNF may
promote the recruitment and proliferation of M1 macro-
phages; persistent and uncontrolled expansion of these
proinflammatory macrophages is a pivotal mechanism in
MAS development [35,36].
To date, H-ferritin and CD681/H-ferritin1 cells were
correlated significantly with haematological involvement,
serum ferritin and CRP of our MAS patients. These results
suggest potentially new biomarkers evaluating severity of
the MAS clinical picture, possibly improving outcome in
these patients [37,38]. In fact, diagnosis and appropriate
treatments may be delayed, due to non-specific findings in
the early phases of disease, thus new biomarkers may
improve the management of this life-threating syndrome
[39–42]. Although a rigorous process of validation is
needed, the use of novel biomarkers in these patients may
help physicians, thus improving diagnosis with early recog-
nition and prompt therapy as well as predicting response
to treatment and outcome, as suggested in other rheumatic
diseases [43–47].
Our retrospective study shows different limitations. We
evaluated a low number of patients, thus our findings
should be confirmed further. However, it must be pointed
out that MAS is a very rare disease and, as observed for
other infrequent complications during rheumatic diseases,
organizing specifically designed studies may be a challenge
[48–50]. Furthermore, our study did not allow us to indi-
cate if the CD681 macrophages are actively producing fer-
ritin or phagocyting cells and future specifically designed
studies are needed to elucidate these pathogenic steps
entirely during MAS.
In conclusion, H-ferritin, CD681/H-ferritin1 cells
IL-1b, TNF, IFN-g, were increased markedly in BM inflam-
matory infiltrate of MAS patients, possibly involved in a
proinflammatory pathogenic vicious loop. Although future
studies are needed to clarify entirely the possible role of
these features, our results may allow us to hypothesize that
ferritin and CD681/H-ferritin1 macrophages may not only
be considered a consequence of the inflammation but are
involved directly in MAS pathogenesis. Furthermore,
H-ferritin and CD681/H-ferritin1 cells are correlated sig-
nificantly with haematological involvement of our patients,
suggesting possible biomarkers of severity in order to
improve the management of patients, allowing physicians
an early recognition and prompt therapy for this life-
threating syndrome.
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